C
ASP3 is expressed as an inactive pro-enzyme that is activated upon exposure to apoptosis-inducing stimuli 1, 2 . Pro-CASP3 undergoes proteolytic processing by CASP8, 9 and 10 that yields three polypeptides: the pro domain, p17 and p12. The p17 and p12 form a heterodimer that executes the protease activity. CASP3 activates itself as well as CASP6, 7 and 9 by proteolytic cleavage and amplification of the signal for the execution of apoptosis. The therapeutic application of CASP3 is limited because of this complex regulation [3] [4] [5] . We overcome this problem by genetic engineering the CASP3.
Here, a mutant of CASP3 designed to be activated specifically by the aspartate protease of human immunodeficiency virus type 1 (HIV-1), but not by other CASPs, was produced (CASP3*) and a proof-of-concept study was conducted to demonstrate the therapeutic potential of CASP3* against lymphoid malignancies and HIV-1 infection.
To achieve leukemic cell killing by CASP3*, a lentivirus-like nanoparticle (LENA) system was utilized 6 . The LENA system is a simple, efficient and reproducible method that we have developed to transduce proteins into mammalian cells 6 . The LENA is different from lentiviral vector in that the former system delivers proteins that are encapsidated into the nanoparticles but not genes as does the latter. Protein transduction does not require de novo transcription and translation, and the transferred protein functions immediately after the transduction. Also, LENA is biologically safe since LENA is not an ''infectious'' agent. Approximately 5,000 CASP3*-Gag proteins are packaged, processed and activated by HIV-1 protease in the particle of LENA. CASP3*-LENA, facilitated by vesicular stomatitis virus G protein (VSV-G), binds to cells and enters them via endocytosis. Membrane fusion between the cell and LENA takes place at the endosome in a VSV-G-dependent manner. The LENA content is then released into the cell cytoplasm. We expected an initiation of apoptosis in CASP3*-LENA-exposed leukemic cells immediately after membrane fusion.
In the HIV/AIDS field, clinical trials have proved that gene therapy approaches are indeed effective against HIV-1 infection 7, 8 . However, the emergence of treatment-resistant viruses is problematic, since HIV-1 is a highly mutagenic virus. Also, the ''off-target'' effect of therapeutic molecules is a serious concern. Thus, developing a highly specific therapeutic gene against HIV-1 provides another option for treatment of HIV-1-infected individuals in a molecular therapy approach.
In this study, the genetically-engineered CASP3 activated specifically by HIV-1 protease was shown to have therapeutic potential against both lymphoid malignancies and HIV-1 infection.
Results CASP3* has proteolytic cleavage sites for HIV-1 protease adopted from the matrix (MA or p17 Gag (Gag, Fig. 1a ). The myristoylation signal of Lyn was attached at the amino-terminus and serves as a membrane-targeting signal. The pro domain of CASP3 was dispensable for enzyme activity and was removed from this construct. Then, the CASP3* was applied to the LENA system for the leukemic cell killing experiment (Fig. 1b) . The CASP3*-Gag and its proteolytic products were detected in the HIV-1 protease-activable CASP3*. The cellular (gray triangle, digesting D28-S29 and D175-S176 junctions) and HIV-1 (black triangle) protease proteolytic sites are indicated. The CASP3 D28 was replaced with amino acids 127-136 (VSQNYPIVQ) from HIV-1 Gag (according to the HXB2 coordinate). The amino acids 129-134 (QNYPIV) from HIV-1 Gag according to the HXB2 coordinate was inserted after CASP3 D175. HIV-1 protease targets the YP junction. The enzyme is active when the p17 and p12 subunits are dimerized. (b) Production of CASP3*-LENA and its mechanism of action. The CASP3* was placed at the 5' end of wild type (WT) gag-pol to yield CASP3*-gag-pol. The proteolytic cleavage sites within Gag for HIV-1 protease and the proteolytic products are indicated MA, matrix; CA, capsid; and NC, nucleocapsid. The CASP3*-gag-pol and VSV-G expression vectors were co-transfected into 293T cells. Then, the VSV-G-encapsidated LENA containing activated CASP3* protein was produced in the culture supernatant. 293T cell lysate transfected with pCASP3*-gag-pol by Western blot analysis (Fig. 1c, Cell) in a pattern similar to that of wild-type Gagpol (WT, Fig. 1c ). However the processing efficiency of Gag was slightly attenuated in the CASP3* construct compared with WT, as highlighted by the smaller amount of p24 CA relative to its precursor. In the culture supernatant of transfected 293T cells, CASP3*-LENA was detected by Western blot analysis (Fig. 1c, Sup) . The presence of CASP* was verified by Western blot analysis using anti-CASP3 antibody that specifically recognizes the p17 subunit of CASP3 (Fig. 1c, Sup) . In 293T cells transiently transfected with the WT expression plasmid, Gag was evenly distributed in the cell cytoplasm as visualized by an immunofluorescence assay (Fig. 1d) . In contrast, CASP3*-Gag was distributed mainly in the cytoplasm and, to a lesser extent, in the nucleus, forming numerous fine aggregations (Fig. 1d) . Also, some CASP3*-Gag signal was detected at the cell periphery (Fig. 1d) . Despite these differences, LENA production by CASP3*-Gag-pol was as efficient as that by WT; the signal ratio of CASP3*-Gag and its proteolytic products in the virus-like particle (VLP) fraction relative to the cell lysate were comparable to that of the WT (Fig.1c) .
To verify the enzyme activity of CASP3* in LENA, the proteolytic activity of CASP3* was measured using a caspase 3/7-specific substrate, DEVD-aminoluciferin, that luminesces upon cleavage. Significant enzymatic activity was detected in the purified CASP3*-LENA (Fig. 1e) . Importantly, this signal was substantially reduced when proteolytic cleavage of CASP3*-Gag was attenuated through the preparation of CASP3*-LENA in the presence of 0.5 mM HIV-1 protease inhibitor nelfinavir (NFV; Fig. 1e ). These data suggest that active CASP3* is enveloped in the LENA and that the activation of CASP3* is dependent on HIV-1 protease.
HIV-1 protease is fully activated after viral budding. Thus, the majority of CASP3* should be activated outside cells. This minimizes damage to LENA-producing cells by CASP3*. However, LENAproducing 293T cells were damaged upon Gag-pol expression presumably due to the cytotoxicity of the small amount of HIV-1 protease activated in the cell cytoplasm upon overexpression of the protein. Cell viability and LENA production improved when the LENA-producing cells were treated with a low dose of HIV-1 protease inhibitor. Preparation of LENA in the presence of 0.2 mM saquinavir (SQV) increased the LENA yield by approximately 4-fold (Fig. 2a) . Under these conditions, HIV-1 protease in LENA remained active as evidenced by the production of cleavage intermediates of CASP3*-Gag (Fig. 2a) . The activation of CASP3* was not blocked under these conditions because a cleavage intermediate, MA-CA, predicated the release of CASP3* from the precursor (Fig. 2a , arrowhead), and the biological activity of CASP3*-LENA was detected as described below. Similar data were obtained using the low dose of NFV.
For leukemic cell killing by CASP3*-LENA, an acute T cell lymphoblastic leukemia (ALL) cell line, MOLT-4, was chosen. MOLT-4 cell viability was significantly attenuated when cells were exposed to CASP3*-LENA, whereas no cell killing was observed in WT-LENA or non-enveloped CASP3*-LENA at 1d post-LENA exposure ( Fig. 2b and 2c) . A cell metabolism-based cell viability assay revealed that 93.3% of cell viability was lost in CASP3*-LENA-exposed MOLT-4 cells at 1d post-LENA exposure (Fig. 2b ). This cell killing was more efficient when cells were treated with CASP3*-LENA prepared in the presence of 0.2 mM SQV bearing a higher LENA titer (99.2%, Fig. 2b ). The MOLT-4 cells exposed to CASP3*-LENA contained fragmented nuclei with condensed chromatin, characteristic of cells undergoing apoptosis (Fig. 2d ). Such nuclear morphology was not found in MOLT-4 cells exposed to WT-LENA or nonenveloped CASP3*-LENA. Induction of apoptotic cell death was detected at 6 h post-LENA exposure by Annexin V staining (Fig. 2e) . The VSV-G functional inhibitor Bafilomycin A1, which prevents the endosome acidification required for the activation of VSV-G, rescued the cells from apoptotic cell death at 12.5 ng ml 21 (Fig. 2c-f) . A cell-permeable CASP3 inhibitor, Z-DEVD-FMK, also protected cells from CASP3*-LENA-induced apoptosis at 0.5 mM (Fig. 2c-g ). These data suggest that the cell death induced by CASP3*-LENA is dependent on VSV-G function and the proteolytic function of CASP3*. The death inducing titer of CASP3*-LENA for MOLT-4 cell was 2.0 3 10 6 particles per milliliter, which was estimated from the dose-dependent cell killing kinetics using serially diluted CASP3*-LENA preparations (average of four independent experiments).
In addition to MOLT-4 cells, CASP3*-LENA induced apoptosis in two more leukemic cell models, SUP-T1 cells, a pleural effusion T cell lymphoblastic lymphoma cell line, and the HTLV-1-transformed T cell line M8166, a model for adult T cell leukemia (ATL, Fig. 2g ). Similar data were obtained in the human chronic myelogenous leukemia (CML)-derived cell line K562 and the neuroblastoma cell line NP-2 (data not shown). These data indicate that the cell killing activity of CASP3*-LENA is not restricted to the leukemic cells. In these experiments, WT-LENA and non-enveloped CASP3*-LENA failed to induce apoptosis. These data demonstrate the attractiveness of CASP3* protein transduction by LENA as a tool for molecular cancer therapy. The cell killing activity of CASP3*-LENA was not detected in primary blood mononuclear cells (data not shown). This is presumably because the primary cells are inefficient to the LENAmediated protein delivery and/or to the CASP3-induced apoptosis, or both. This suggests that the CASP3*-LENA may favor cancer cells to induce apoptotic cell death. CASP3* was also applied to limit HIV-1 replication. We hypothesized that CASP3*-expressing T cells may be more susceptible to apoptosis upon HIV-1 infection due to the expression of HIV-1 protease in infected cells. To this end, SUP-T1 cells were transduced with CASP3* using a murine leukemia virus (MLV) vector, and two independently isolated pairs of SUP-T1 cells were analyzed (Fig. 3a) . The rate of cell proliferation and the susceptibility to apoptosis induced by a serim depriviation in SUP-T1/CASP3* cells were indistinguishable from those in SUP-T1/Cont cells (data not shown). Cells were exposed to a low-or high-dose HIV-1 preparation and viral replication was monitored. In both isolates, HIV-1 propagation in SUP-T1/CASP3* cells was attenuated regardless of the HIV-1 exposure dose (Fig. 3b) . These data suggest that CASP3* can limit the propagation of HIV-1 in tissue culture.
To determine the mechanism by which HIV-1 replication is blocked, the viral entry phase and the production phase were investigated separately. If the virus-associated protease is responsible for the activation of CASP3* at the viral entry phase, infection with the HIV-1-based lentiviral vector should also kill SUP-T1/CASP3* cells. Thus, the establishment efficiency of lentiviral vector infection in SUP-T1/CASP3* cells should be lower than that in control cells. To test this, SUP-T1/CASP3* cells were infected with a lentiviral vector expressing luciferase upon establishment of infection. The luciferase activity in SUP-T1/CASP3* cells at 4 d post-infection was lower than in the control cells (Fig. 3c) . On the other hand, the levels of MLV-transduced luciferase activity in SUP-T1/ CASP3* cells were similar to those in the control cells (Fig. 3c) . Note that CASP3* was not activated by MLV since the substrate preference of MLV protease is distinct from that of HIV-1 protease. These data suggest that virus-associated HIV-1 protease is capable of activating CASP3* to induce apoptosis in SUP-T1/CASP3* cells. Luciferase activity was still detected in the lentiviral vector-infected SUP-T1/CASP3* cells (Fig. 3c) , implying that some cells might have lost the high-level expression of CASP3* or a single virion-associated protease might not be able to initiate CASP3* activation at levels sufficient to kill all of the infected cells. Next, the induction of apoptosis by the virion-associated viral protease was examined directly. SUP-T1/CASP3* cells were exposed to HIV-1 and the cells were probed with Annexin V. Cont cells underwent apoptosis, which was lowered by NFV (Fig. 3d) , suggesting that the HIV-1 infection induces apoptotic cell death in a HIV-1 protease-dependent manner as previously reported 9, 10 . By contrast, the apoptotic cells was detected more frequently in SUP-T1/CASP3* cells than in SUP-T1/Cont cells (6.3% and 5.0% in two independent experiments), which was drastically decreased to 1.2% in the presence of NFV (Fig. 3d) . These data suggest that the CASP3* predispose cells to undergo apoptosis upon HIV-1 infection, and the virus-associated protease is responsible for the induction of apoptosis.
To examine the viral production phase, the HIV-1 gag-pol was transduced into SUP-T1/CASP3* cells by MLV vector, and the levels of Gag were evaluated. If HIV-1 protease activity in virus producing cells is responsible for the activation of CASP3*, then the expression of Gag-pol, not Gag, should confer the cell growth disadvantage, resulting in reduced levels of Gag in these cells. Transfected SUP-T1/CASP3* cells were subjected to Western Blot analysis at 7 d postinfection. The levels of Gag and its proteolytic products in SUP-T1/ CASP3* cells were indistinguishable from those of the control cells (Fig. 3e) . Similar results were obtained when SUP-T1/CASP3* cells were transfected with a plasmid expressing HIV-1 Gag-pol (Fig. 3e) . These data indicate that the attenuation of HIV-1 replication in SUP-T1/CASP3* cells is due to the activation of CASP3* by virion-associated HIV-1 protease at the viral entry phase, leading to the depletion of virus-infected cells from the culture by apoptosis. In agreement with this model, the inhibition of apoptosis by Z-DEVD-FMK enhanced the efficiency of HIV-1 replication (data not shown).
Discussion
This study provides evidence that CASP3* has therapeutic potential against cancer and HIV-1 infection, overcoming the potential difficulty of CASP3 for the application to human gene therapy 3, 4, 11 . The cancer therapy by CASP3*-LENA may be more applicable to solid tumors due to the current technological limit in particle delivery. However, to apply the CASP3*-LENA approach to the cancer therapy, it is critical to improve the potency of CASP3*-LENA. This is because the cell killing activities of CASP3*-LENA in some transformed cells, including MT-4, a HTLV-1-transformed human T cell line, were undetectable although the LENA-mediated protein delivery by LENA has been shown to be highly efficient in MT-4 cells 6 . MT-4 cells are highly resistant to apoptosis because they express potent anti-apoptotic genes, such as HTLV-1 Tax [12] [13] [14] . The Tax induces expression of intracellular caspase inhibitor, cFLIP, which inhibits the activation cycle of CASPs 15, 16 . Cancer cells often express high levels of cellular inhibitor of apoptosis protein (CIAP), which may lower the susceptibility of cells to apoptosis induced by CASP3. We may be able to overcome this issue by generating a CASP3* mutant that does not interact with CIAP. The potentiation of CASP3*-LENA should also contribute to reduce the number of injections necessary to achieve the therapeutic effect. Additionally, for clinical applications, a regulatory system to control the cell tropism of LENA needs to be developed.
For HIV-1 infection, CASP3* may be applicable to adoptive stem cell therapy, alternatively termed intracellular vaccination. Stem cell gene therapy has been shown to be effective in clinical trials against HIV-1 infection, as has shRNA therapy targeting CCR5 mRNA 7 . Gene therapy using a zinc finger nuclease was found to be effective against HIV-1 infection as well 8 . These therapeutic approaches target nucleic acids, and off-target effects represent a serious concern. CASP3* is designed to be activated specifically by HIV-1 protease; thus, it offers a basis for a novel therapeutic approach with few "off-target" effects. CASP3* induces suicide in HIV-1-infected cells, and does not yield latently-infected cells. The CASP3* approach should be effective against drug-resistant HIV-1 strains since the anti-viral mechanism of CASP3* is distinct from those of currently-available anti-retroviral drugs. Furthermore, a CASP3*-resistant HIV-1 may not emerge easily. This is because mutations in viral protease that do not affect Gag processing but also do not activate CASP3* are unlikely to occur. Additionally, our strategy is applicable to other infectious diseases if the infectious agents encode proteases with unique substrate preferences. In summary, our work provides a platform for the development of a CASP3*-based therapy against cancer and HIV-1 infection.
Methods
Plasmids. CASP3 was amplified from MT-4 total RNA using a two-step PCR protocol. For the first reaction, two RT-PCR reactions were performed using the following primer sets: fwd #1 5'-acc ggt cAG CCA GAA CTA Ccc cat cgt gca gTC Tgg aat atc cct gga caa c-3' and rev #1 5'-CTc acg atg ggG TAG TTC TGg tct gtc tca atg cca cag tc-3'; and fwd #2 5'-acC AGA ACT ACc cca tcg tgA GTG GTG TTG ATG ATG ACA TGG-3' and rev #2 5'-CAA TTG GTG ATA AAA ATA GAG TTC TTT TG-3'. The second PCR reaction was performed using fwd #1 and rev #2 primers targeting the products obtained in the first RT-PCR reactions. The AgeI-MfeI fragment of the PCR product was cloned into AgeI-EcoRI sites of plynMyGFP-gag-pol 6 , generating pCASP3*-gag-pol. The retroviral expression vector pQcCASP3* was constructed by amplifying CASP3* by PCR as detailed above using 5'-acc ggt gcc acc ATG ggc TCT gga ata tcc ctg gac aac-3' and 5'-CAA TTG TTA GTG ATA AAA ATA GAG TTC TTT TG-3', and cloned into AgeI-EcoRI sites of pQcXIP (Clontech, Palo Alto, CA). The pCMMP Gagf vector was constructed by cloning a XhoI-BamHI fragment from pGag-GFP 17 into the corresponding restriction sites of pCMMP KRAB
18
. The pCMMP HIV-1 gag-pol IRES GFP was constructed by three step cloning. First, the AgeI-BamHI KRAB gene fragment from pCMMP KRAB was cloned into the corresponding restriction sites of pCMMP LacZ IRES GFP 9 , generating pCMMP KRAB IRES GFP. The AgeI-EcoRI BlaM gene fragment amplified from pUC19 by PCR 6 was cloned into the AgeI-MfeI sites of pCMMP KRAB IRES GFP, generating pCMMP BlaM IRES GFP. The EcoRI-XhoI HIV-1 gag-pol gene fragment from pgagpol 18 was cloned into the corresponding restriction sites of pCMMP BlaM IRES GFP, generating pCMMP HIV-1 gag-pol IRES GFP. The HIV-1 proviral DNA pNL4-3 was obtained from the NIH AIDS Research and Reference Program. The HIV-1 Gag expression vector pHIV-1 Gagf was produced by cloning an AgeI-BamHI fragment from pHIV-1 Gagf-GFP 17 into the corresponding sites of pEGFP-C2 (Clontech).
Cells, viability assay, and transfection. Cells were maintained in RPMI 1640 medium (Sigma, St. Louis, MA) supplemented with 10% fetal bovine serum (Japan Bioserum, Tokyo), 100 U ml 21 penicillin, and 100 mg ml 21 streptomycin (Invitrogen), at 37uC in a humidified 5% CO 2 atmosphere. Cells were transfected with Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Bafilomycin A1 was used at a concentration of 12.5 ng ml 21 (Sigma), and a CASP3 inhibitor, Z-DEVD-FMK, was used at a concentration of 0.5 mM (BioVision, Mountain View, CA). The HIV-1 protease inhibitors nelfinavir (NFV) and saquinavir (SQV) were obtained from the NIH AIDS Research and Reference Reagent Program. To produce VSV-G-pseudotyped LENA, 200 ng pVSV-G (Clontech) and 2 mg pCASP3*-gag-pol or pgag-pol 18 were transfected into 293T cells. Non-enveloped LENA was produced using pcDNA3 (Invitrogen) in place of pVSV-G. The LENA preparation was passed through nitrocellulose filters (0.45 mm). Cell viability was scored by the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega). For the transfection of plasmids into SUP-T1 cells, a DEAE-dextran protocol was employed. Five million cells were resuspended in 250 ml of STBS (25 mM TrisCl, pH 7.4, 137 mM NaCl, 5 mM KCl, 0.6 mM Na 2 HPO 4 , 0.7 mM CaCl 2 , and 0.5 mM MgCl 2 ), including 10 mg of plasmid DNA. Cells were mixed with 250 ml of STBS containing 1 mg ml -1 of DEAE-dextran and incubated for 30 min at room temperature (RT). The cells were then incubated with STBS containing 10% DMSO for 2 min at RT and washed with 1 ml HBSS (Invitrogen).
Protein transduction. Protein transduction was performed as described previously by incubating approximately 1 3 10 6 cells with 1 ml LENA-containing culture medium at 37uC 3 .
Immunological detection. The detection of viral gene products by Western blot analysis was performed as described previously 19 , except that the anti-p24 CA monoclonal antibody clone 183-H12-5C and anti-CASP3 p17 subunit polyclonal antibody (Cat. # AB3623, Millipore, Tokyo, Japan) were used. Immunofluorescent analysis was performed as described previously using the same monoclonal antibody 18 . Signals were detected using an LAS-3000 mini Lumino-Image analyzer operated by the LAS-300mini Image Reader software (ver.2.2, Fuji Film, Tokyo, Japan). The brightness and contrast of the image were adjusted using Adobe Photoshop (ver.7.0, Adobe, Tokyo, Japan).
Microscopy. Cells were imaged by confocal fluorescence microscopy (LSM510 Meta, Carl Zeiss MicroImaging Inc., Tokyo, Japan). For the imaging of nuclei, multiple focal planes were projected to generate a single image.
Virus production and infection. The HIV-1, lentiviral and MLV vectors used have been described previously 9 . The pQcXIP was used as a control for pQcCASP3*. Detection of CASP3 enzymatic activity. The substrate for the CASP3 enzyme assay was purchased from Promega (Caspase-Glo 3/7 Assay System, Promega, Madison, WI). Luciferase activity was measured using the Steady-Glo Luciferase Assay system (Promega). Luminescence was detected using a Veritas TM Microplate Luminometer (Promega).
Annexin V apoptosis assay. Cells were analyzed by flow cytometry using the Vybrant Apoptosis Assay kit (Invitrogen).
Enzyme-Linked Immunosorbent Assay (ELISA). A p24 ELISA was conducted according to the manufacturer's protocol (Zeptometrics, Buffalo, NY). To measure cellular p24, transfected 293T cells were washed once with PBS, lysed in 500 ml buffer A (described above) for 30 min, and then subjected to the ELISA.
